Drug Profile
GSK 2239633
Alternative Names: GSK2239633Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiasthmatics
- Mechanism of Action CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Netherlands (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Netherlands (PO)